Insider · CIK 0001992324
Ryan Savitz
Files at DNTH (Dianthus Therapeutics, Inc. /DE/). First filing Sep 11, 2025, latest Jul 13, 2026.
In brief
Ryan Savitz files SEC Form 4 as CFO at DNTH (Dianthus Therapeutics, Inc. /DE/). Since Sep 11, 2025, Ryan Savitz has reported 0 open-market buys worth $0 and 5 open-market sells worth $15M, the latest filed on Jul 13, 2026.
A track record needs three past buys with six months of prices behind them; Ryan Savitz has 0, so none is measured yet.
The newest scored trade: sold $3.2M of DNTH on Jul 9, 2026, filed Jul 13, 2026, scored 32 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 4 sells worth $14M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Dianthus Therapeutics, Inc. /DE/ | $3.2M 31,249 shares | -100% | +433% from low0% from high | |
| 36Weak | Dianthus Therapeutics, Inc. /DE/ | $739k 8,224 shares | -100% | +488% from low0% from high | |
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | $9.5M 114,367 shares | -100% | +465% from low-3% from high | |
| 31Weak | Dianthus Therapeutics, Inc. /DE/ | $904k 20,000 shares | -100% | +201% from low0% from high | |
| 28Weak | Dianthus Therapeutics, Inc. /DE/ | $700k 20,000 shares | -100% | +139% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 9, 2026 | DNTH Dianthus Therapeutics, Inc. | 31,249 0.06% of outstanding | $3.1M | Jul 9, 2026 | none |
| Apr 9, 2026 | DNTH DIANTHUS THERAPEUTICS INC | 8,224 0.02% of outstanding | $719k | Apr 9, 2026 | $9.5M |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. | 114,367 0.26% of outstanding | $9.1M | Mar 31, 2026 | none |
| Dec 4, 2025 | DNTH DIANTHUS THERAPEUTICS INC | 20,000 0.05% of outstanding | $879k | Dec 4, 2025 | $700k |
| Sep 9, 2025 | DNTH Dianthus Therapeutics, Inc. | 20,000 0.06% of outstanding | $636k | Sep 9, 2025 | none |
Transactions
Every row this insider has filed, 29 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +31,249 | $21.77 | $680k | 31,249 | Jul 13, 2026 |
| Jul 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -10,354 | $100.22 | $1.0M | 20,895 | Jul 13, 2026 |
| Jul 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -15,329 | $101.24 | $1.6M | 5,566 | Jul 13, 2026 |
| Jul 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -5,566 | $101.97 | $568k | 0 | Jul 13, 2026 |
| Jul 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -31,249 | $0.00 | $0 | 68,751 | Jul 13, 2026 |
| Apr 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +8,224 | $17.88 | $147k | 8,224 | Apr 10, 2026 |
| Apr 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -8,224 | $89.84 | $739k | 0 | Apr 10, 2026 |
| Apr 9, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,224 | $0.00 | $0 | 71,776 | Apr 10, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +74,367 | $8.44 | $628k | 74,367 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +40,000 | $17.88 | $715k | 114,367 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -1,390 | $78.33 | $109k | 112,977 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -21,825 | $78.86 | $1.7M | 91,152 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -1,485 | $80.25 | $119k | 89,667 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -800 | $81.36 | $65k | 88,867 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -2,366 | $82.84 | $196k | 86,501 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -59,800 | $83.90 | $5.0M | 26,701 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -19,469 | $84.57 | $1.6M | 7,232 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -7,232 | $85.54 | $619k | 0 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -74,367 | $0.00 | $0 | 10,399 | Apr 1, 2026 |
| Mar 31, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 80,000 | Apr 1, 2026 |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 4, 2026 |
| Dec 4, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +20,000 | $8.44 | $169k | 20,000 | Dec 5, 2025 |
| Dec 4, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -20,000 | $45.18 | $904k | 0 | Dec 5, 2025 |
| Dec 4, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +20,000 | $0.00 | $0 | 84,766 | Dec 5, 2025 |
| Sep 23, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Sep 25, 2025 |
| Sep 9, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +20,000 | $8.44 | $169k | 20,000 | Sep 11, 2025 |
| Sep 9, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -20,000 | $35.00 | $700k | 0 | Sep 11, 2025 |
| Sep 9, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +20,000 | $0.00 | $0 | 104,766 | Sep 11, 2025 |
| Feb 3, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 4, 2025 |
Questions about Ryan Savitz
Answered from the filings on this page, as of the latest one.
Is Ryan Savitz buying or selling?
In the last 12 months Ryan Savitz reported 0 open-market buys worth $0 and 4 open-market sells worth $14M on SEC Form 4; the latest was sold $3.2M of DNTH on Jul 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Ryan Savitz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ryan Savitz has 0.
Where does Ryan Savitz file Form 4?
Ryan Savitz has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/) as EVP, CFO & CBO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.